Cipla Receives US FDA Approval for Generic Advair Diskus Across All Three Strengths

What Happened ?

Cipla announced that it has received approval from the United States Food and Drug Administration (USFDA) for its ANDA covering Generic Advair Diskus® (fluticasone propionate and salmeterol inhalation powder) in all three strengths:

• 100/50 mcg
• 250/50 mcg
• 500/50 mcg

The approved product is a therapeutically equivalent version of Advair Diskus®, which is widely prescribed for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Commercial launch in the United States is planned during Q2 FY27. 

key details

Product & Business Highlights:

• Received USFDA approval for Generic Advair Diskus® across all three dosage strengths.
• Marks Cipla’s first dry powder inhaler (DPI) approval from its U.S.-based manufacturing network.
• Product addresses the treatment of asthma and COPD.
• The addressable U.S. market is valued at approximately US$908 million.
• Approval strengthens Cipla’s respiratory franchise and enhances its presence in the complex inhalation products segment.
• The product is expected to be commercially launched during Q2 FY27.
• The approval is supported by Cipla’s vertically integrated inhalation platform and investments in U.S. manufacturing capabilities. 

Note:

• This approval represents an important milestone in Cipla’s strategy to expand complex respiratory therapies manufactured in the United States while strengthening supply reliability for the North American market. 

Risk Analysis

Summary:

• While the regulatory approval is a positive development, the commercial success of the product will depend on execution of the U.S. launch and competitive market dynamics.

Key Risks:

• Successful commercial launch in Q2 FY27 is essential to realize revenue potential.
• Competition within the U.S. generic respiratory market could affect market share.
• Manufacturing scale-up and supply chain execution will be critical following approval.
• Pricing pressure in the U.S. generics market may impact profitability.

Worst Case:

• Delayed commercialization, pricing pressure, or slower-than-expected market adoption could limit the revenue contribution from the newly approved product.

Risk Level: Medium

Company Commentary

Management highlighted the following during the quarter:

• The approval reinforces Cipla’s commitment to expanding access to complex respiratory therapies in the U.S.
• Management highlighted the company’s expertise in developing and scaling sophisticated inhalation products.
• Cipla stated that the approval demonstrates the strength of its vertically integrated inhalation platform and continued investments in U.S. manufacturing.
• The approval marks the first dry powder inhaler manufactured from Cipla’s New York facility, strengthening its long-term respiratory portfolio.